BRAF and non-small cell lung carcinoma: In addition, two groups independently reported that YAP overexpression confers BRAF inhibitor resistance in BRAF-mutant melanoma and non-small cell lung cancer (NSCLC)5,6, which suggested that YAP inhibition could overcome BRAF inhibitor resistance in BRAF-mutant cancer cells.